FDA approves combo of Jazz’s lurbinectedin and Roche’s atezolizumab for ES-SCLC

The Food and Drug Administration has approved lurbinectedin, or Zepzelca, from Jazz Pharmaceuticals (JAZZ) in combination with atezolizumab, or Tecentriq, from Roche’s (RHHBY) Genentech, or atezolizumab and hyaluronidase-tqjs, or Tecentriq Hybreza, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer, or ES-SCLC, whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.